AHT-434 is under clinical development by Alterity Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AHT-434’s likelihood of approval (LoA) and phase transition for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) took place on 26 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AHT-434 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AHT-434 overview

AHT-434 (PBT-434) is under development for the treatment of Parkinson's disease and movement disorders including multiple system atrophy, corticobasal degeneration and progressive supranuclear palsy. PBT434 is administered orally. PBT434 is a metal-protein attenuating compound (MPAC). PBT434 has a potent influence on iron, alpha-synuclein and the protein DJ-1.

Alterity Therapeutics overview

Alterity Therapeutics, formerly Prana Biotechnology, is a developer of therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer’s disease, brain cancer and other major age-related degenerative disorders. It is developing first-in-class therapies for the treatment of neurodegenerative disease. Alterity Therapeutics develops technology platform in association with various institutions and medical institutes. The company also maintains a library of metal protein attenuating compounds that may support new therapies for neurodegenerative disease. It also conducts various clinical programs. The company develops a proprietary library of MPACs. It collaborates with various universities for its research projects. Alterity Therapeutics is headquartered in Melbourne, Victoria, Australia.

Quick View AHT-434 LOA Data

Report Segments
  • Innovator
Drug Name
  • AHT-434
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.